Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report report published on Monday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $20.00 target price on the stock.

A number of other research analysts have also commented on the stock. Truist Financial lifted their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada boosted their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Piper Sandler reaffirmed an “overweight” rating and set a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Finally, Citigroup reiterated an “underperform” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Trading Down 3.5%

Shares of NASDAQ FULC opened at $9.51 on Monday. The stock has a market cap of $514.68 million, a P/E ratio of -8.06 and a beta of 3.20. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74. The stock has a 50 day moving average of $10.70 and a two-hundred day moving average of $8.79.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider directly owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 4,205,139 shares of company stock valued at $58,711,943. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in shares of Fulcrum Therapeutics in the first quarter valued at $164,000. Jane Street Group LLC grew its stake in Fulcrum Therapeutics by 62.1% in the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after acquiring an additional 45,157 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Fulcrum Therapeutics by 865.0% during the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after acquiring an additional 308,854 shares in the last quarter. Strs Ohio acquired a new position in Fulcrum Therapeutics during the first quarter worth about $263,000. Finally, Aberdeen Group plc acquired a new position in Fulcrum Therapeutics during the second quarter worth about $404,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.